Exploring Developments and Challenges of Immunological Approaches in AML Treatment
Eduardo Rego, MD, PhD, University of São Paulo, Brazil, discusses what he most looks forward to in regards to presentations and discussions at the 2024 Society of Hematologic Oncology (SOHO) meeting in Houston, Texas.
Dr Rego emphasized his particular interest in data in acute myeloid leukemia (AML) treatment development, particularly the incorporation of different immunological approaches and the challenges which still remain to be addressed with widely utilizing such treatments.
Transcript:
Hello, my name is Eduardo Rego. I work for the University of São Paulo in Brazil. There [are] many important talks [at SOHO 2024], but my area of interest [is] mainly acute leukemias. I'm eager to hear about the incorporation of different immunological approaches in the treatment of acute leukemias.
This [type of treatment] has been going on for acute lymphoblastic leukemia (ALL) for some time, but now we have some results also about acute myeloid leukemia. I'm very interested to know what hurdles are still in order to implement this strategy for a broader number of patients.
© 2024 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of OLN or HMP Global, their employees, and affiliates.
